Roundup

Five things for pharma marketers to know: Monday, September 26, 2022

Lecia Bushak

September 26, 2022

5:00 am

NIH allocates $600 million to fund ‘human genome project’ brain research; Congress renews FDA user fee program; Eleven people die in confirmed Ebola cases in Uganda.

Five things for pharma marketers to know: Friday, September 23, 2022

Jack O'Brien

September 23, 2022

5:00 am

Novartis prioritizes U.S. market despite drug pricing laws; Vaccinators report weeks-long delays in shipments of Moderna’s updated COVID-19 boosters; Goldman Sachs says Revance Therapeutics is working on a Botox rival drug.

Five things for pharma marketers to know: Thursday, September 22, 2022

Jack O'Brien

September 22, 2022

5:00 am

W.V. reaches $147.5 million opioid settlement with CVS and Walmart; President Biden’s drug pricing legislation targets senior voters; Juul sues the FDA over documents supporting e-cigarette ban.

Five things for pharma marketers to know: Wednesday, September 21, 2022

Jack O'Brien

September 21, 2022

5:00 am

NYC lifts COVID-19 vaccine mandates for private sector; DOJ charges 47 in $250 million pandemic food program scheme; Merck to launch a late-stage study for lower-dose versions of its HIV treatment.

Five things for pharma marketers to know: Tuesday, September 20, 2022

Jack O'Brien

September 20, 2022

5:00 am

U.S. health officials call for new STD prevention and treatment efforts; Federal court hears J&J’s talc bankruptcy oral arguments; Teva to start paying opioid settlement in 2023.

Five things for pharma marketers to know: Monday, September 19, 2022

Lecia Bushak

September 19, 2022

5:00 am

Congress faces its deadline to reauthorize FDA’s user fee program; Intellia Therapeutics’ CRISPR-based gene editing treatment shows potential; AbbVie and BMS to lay off 360 employees.

Five things for pharma marketers to know: Friday, September 16, 2022

Jack O'Brien

September 16, 2022

5:00 am

Experts warn U.S. about upcoming flu season; CDC says monkeypox outbreak is slowing; Adderall supplies run low as demand rises.

Five things for pharma marketers to know: Thursday, September 15, 2022

Lecia Bushak

September 15, 2022

5:00 am

Capstan Therapeutics launches with $165 million in hand; Sen. Graham introduces federal abortion ban bill; Pfizer begins U.S. trial for mRNA flu vaccine.

Five things for pharma marketers to know: Wednesday, September 14, 2022

Jack O'Brien

September 14, 2022

5:00 am

U.S. records first monkeypox death; Enterovirus causing polio-like muscle weakness spreads among kids; President Biden touts drug pricing law.

Five things for pharma marketers to know: Tuesday, September 13, 2022

Lecia Bushak

September 13, 2022

5:00 am

Biden appoints head for ARPA-H; FDA to review Perrigo’s OTC birth control pill; Microsoft partners with Novo Nordisk on AI.

Five things for pharma marketers to know: Monday, September 12, 2022

Jack O'Brien

September 12, 2022

5:15 am

NY declares polio state of emergency; Officials consider expansion of monkeypox vax eligibility; Companies quietly eliminate vaccine mandates.

Five things for pharma marketers to know: Friday, September 9, 2022

Lecia Bushak

September 9, 2022

5:00 am

Biden administration to begin fall booster rollout; FDA panel recommends Amylyx’s ALS drug; Arcutis acquires Ducentis.

Five things for pharma marketers to know: Thursday, September 8, 2022

Lecia Bushak

September 8, 2022

5:00 am

U.S. expands monkeypox vaccine distribution locations through $20 million partnership with AmerisourceBergen; New York lifts mask mandates for mass transit; Amylyx completes second meeting with Food and Drug Administration advisory committee.

Five things for pharma marketers to know: Wednesday, September 7, 2022

Jack O'Brien

September 7, 2022

5:00 am

Millions of doses of new COVID booster shots rolling out; Republican campaigns go silent on healthcare; White House gambling that a little-studied vaccine can stop monkeypox

Five things for pharma marketers to know: Tuesday, September 6, 2022

Jack O'Brien

September 6, 2022

5:00 am

White House suspends COVID tests program; U.K. pharma bosses face repercussions from watchdog ruling; Contaminant in top-selling drugs linked to cancer.